Chen Shih-Feng, Chiang Yang-Jen, Huang Chiu-Ching
Department of Nephrology, Chang Gung Memorial Hospital, Taipei, Taiwan.
J Formos Med Assoc. 2003 Aug;102(8):570-3.
Sirolimus is a recently licensed immunosuppressant for organ transplantation that has been used as basic, adjuvant, or maintenance therapy for prevention of organ rejection. Well-known side effects of this agent are hyperlipidemia and bone marrow suppression. Interstitial pneumonitis is a relatively newly described adverse effect of the drug. A 43-year-old female recipient of a cadaveric kidney developed cough with blood-tinged sputum while receiving sirolimus immunosuppressive therapy. High-resolution computed tomographic scan and chest radiograph revealed interstitial infiltrations over bilateral lower lungs. No evidence of bacterial, fungal, mycobacterial, or viral infection was found and all tests for collagen vascular diseases were negative. Discontinuation of sirolimus resulted in a significant improvement of the lung disease.
西罗莫司是一种最近获批用于器官移植的免疫抑制剂,已被用作预防器官排斥反应的基础、辅助或维持治疗药物。该药物众所周知的副作用是高脂血症和骨髓抑制。间质性肺炎是该药物相对较新描述的一种不良反应。一名43岁的尸体肾女性受者在接受西罗莫司免疫抑制治疗时出现咳嗽伴痰中带血。高分辨率计算机断层扫描和胸部X线片显示双侧下肺有间质浸润。未发现细菌、真菌、分枝杆菌或病毒感染的证据,所有胶原血管疾病检测均为阴性。停用西罗莫司后,肺部疾病有显著改善。